Compare EZGO & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EZGO | PRFX |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.6M |
| IPO Year | 2020 | 2020 |
| Metric | EZGO | PRFX |
|---|---|---|
| Price | $1.01 | $1.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 77.8K | ★ 193.8K |
| Earning Date | 07-01-2025 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.01 | $0.58 |
| 52 Week High | $3.30 | $5.39 |
| Indicator | EZGO | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 45.59 | 42.77 |
| Support Level | $0.88 | $0.97 |
| Resistance Level | $1.33 | $1.23 |
| Average True Range (ATR) | 0.12 | 0.09 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 29.24 | 29.06 |
EZGO Technologies Ltd is engaged in the sale of e-bicycles and battery and e-bicycle rentals, complemented by the sale of battery packs, battery cell trading and charging pile business. Its product categories include e-bicycle, Intelligent unmanned patrol car, e-motorcycle and e-moped and urban style e-tricycle. Its segments include the Battery cells and packs, electronic control system and intelligent robot segment. and the E-bicycle sales segment. The company generates maximum revenue from the Battery cells and packs segment.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.